We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02567383
Recruitment Status : Unknown
Verified July 2020 by Shin Kong Wu Ho-Su Memorial Hospital.
Recruitment status was:  Recruiting
First Posted : October 5, 2015
Last Update Posted : July 28, 2020
Sponsor:
Information provided by (Responsible Party):
Shin Kong Wu Ho-Su Memorial Hospital

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Clinical experience of with hyperthermia combined with radiotherapy and chemotherapy for recurrent head and neck cancer is limited. The primary goals of hyperthermia combined with CCRT on recurrent head and neck cancer are tumor response rate, while secondary goals are rates of acute and late adverse effects, local control rate, distant metastasis rate, progression-free rate and overall survival rate.

Condition or disease Intervention/treatment Phase
Recurrent Head and Neck Cancer Radiation: Radiation Device: Hyperthermia; Thermotron RF-8 Drug: Cisplatin Drug: Taxotere Phase 2

Detailed Description:
Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia for 40 minutes within 2hr after irradiation, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will be cisplatin 20mg/m2 and taxotere 10-12mg/m2 per week for 6 weekly cycles on the day before radiotherapy and hyperthermia treatment. The two chemotherapy agents will be given in only one day every week, according to the weekly dose. According to Gehan two-stage design, provided the estimated tumor response rate using this regimen is about 40% and objective tumor response is observed in ≥1 of the first 6 patients enrolled, α<0.05 will be achieved indicating a preliminary efficacy. Then the Gehan second stage will be started. With a set of 5% precision and an assumption of 10% dropout rate, 39 additional patients will be enrolled in the Gehan second stage depending on the actual number with tumor response in the Gehan first stage (totaling 45 patients when counting the first 6 in the Gehan first stage). The tumor response, adverse effects and various survival curves will be analyzed.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Clinical Trial Evaluating the Safety and Efficacy of Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer
Study Start Date : September 2015
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Hyperthermia
Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
 Radiation: Radiation
5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks

Device: Hyperthermia; Thermotron RF-8
40 minutes within 2hr after irradiation

Drug: Cisplatin
20mg/m2 per week for 6 weekly cycles before radiotherapy

Drug: Taxotere
10-12mg/m2 per week for 6 weekly cycles before radiotherapy


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Tumor response rate [ Time Frame: 12 Weeks ]
    To estimate the tumor response rate (complete response + partial response; CR + PR; according to RECIST criteria version 1.1) using hyperthermia combined with CCRT for recurrent head and neck cancer.


Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Within 3 months ]
    To estimate rates of each grade adverse events (CTCAE, version 4.0) which is possibly, probably, or definitely related to treatment and which occurs within 3 months from the start of radiation combined with hyperthermia and chemotherapy.

  2. Late adverse events [ Time Frame: After 3 months ]
    To estimate rates of late adverse events (3 months from start of radiation combined with hyperthermia and chemotherapy)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age of 20-85 years, with ECOG performance 0-2.
  2. Treatment failure head and neck cancer, with histologically or clinically confirmed recurrence or progression after previous treatment of radiotherapy with combinations.
  3. Complete surgical excision is NOT feasible as salvage treatment for the recurrent or progressive tumor(s), or the patient does NOT agree to receive the surgical procedure.
  4. Salvage radiotherapy is possible, and a total dose of 50Gy/22fx is considered tolerable.
  5. Measurable lesions by image examinations or endoscopy within 2 months.
  6. The distribution of the lesions of interest does NOT exceed 20cm range.
  7. The patient can tolerate implementation of cisplatin and taxotere weekly therapy, with respect to hematopoietic status, renal function, liver function, allergy and other potential adverse effects.
  8. There is NO other effective treatment option according to the evaluation of physicians.

Exclusion Criteria:

  1. Re-irradiation of 50Gy/22fx is considered NOT tolerable.
  2. Future tumor response to treatment in this study is NOT possibly evaluated using image examinations or endoscopy.
  3. The patient is participating in other clinical trials.
  4. Future regular clinical follow-up is NOT possible.
  5. The patient has large-area metallic implants or tattoos including much metal powder within hyperthermia field (not including metallic hemoclips with small area and few numbers).
  6. The patient has pacemakers, electrocardiograph, defibrillator implanted, or adhesive skin patches including conductive metal.
  7. The patients with ocular or cerebral disorders within hyperthermia field.
  8. Tumor invasion of great or large vessels exists, or patients with any existing complications that may pose risks to hyperthermia treatment.
  9. Patients who have difficulty with communication.
  10. Other patients who are considered to have a contraindication to hyperthermia treatment.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02567383


Contacts
Layout table for location contacts
Contact: Kwan-Hwa Chi, M.D. 886-2-28332211 ext 2274 M006565@ms.skh.org.tw
Contact: Kai-Lin Yang, M.D. 886-2-28332211 ext 2275 M011360@ms.skh.org.tw

Locations
Layout table for location information
Taiwan
Shin Kong Wu Ho-Su Memorial Hospital Recruiting
Taipei, Taiwan
Contact: Kwan-Hwa Chi, M.D.    886-2-28332211 ext 2274    M006565@ms.skh.org.tw   
Contact: Kai-Lin Yang, M.D.    886-2-28332211 ext 2275    M011360@ms.skh.org.tw   
Sponsors and Collaborators
Shin Kong Wu Ho-Su Memorial Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Shin Kong Wu Ho-Su Memorial Hospital
ClinicalTrials.gov Identifier: NCT02567383    
Other Study ID Numbers: 20150205D
First Posted: October 5, 2015    Key Record Dates
Last Update Posted: July 28, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by Shin Kong Wu Ho-Su Memorial Hospital:
head and neck cancer
hyperthermia, Thermotron RF-8
radiotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperthermia
Fever
Head and Neck Neoplasms
Recurrence
Disease Attributes
Pathologic Processes
Neoplasms by Site
Neoplasms
Body Temperature Changes
 Heat Stress Disorders
Wounds and Injuries
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action